EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice

Cristina Di Giorgio iD, Ginevra Urbani, Silvia Marchianò, Michele Biagioli iD, Martina Bordoni, Rachele Bellini, Carmen Massa, Ginevra Lachi, Luigi Cari iD, Elva Morretta iD, Lucio Spinelli, Maria Chiara Monti iD und 8 weitere

Liver International · 2025-02 · 45 (2)

DOI: 10.1111/liv.16235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 13.01.2025. Verfasst von Cristina Di Giorgio und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Receptors, G-Protein-Coupled, Cholestasis, Liver. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PRIN-2022 n. 20223K7L88, FIS PI24/00148, PI21/00922, PRIN-2022-PNRR n. 20227JB3W.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterised by progressive biliary inflammation and fibrosis, leading to liver cirrhosis and cholangiocarcinoma. GPBAR1 (TGR5) is a G protein‐coupled receptor for secondary bile acids. In this study, we have examined the therapeutic potential of BAR501, a selective GPBAR1 agonist in a PSC model.

Methods

Single‐cell analysis of healthy human liver samples and gene expression analysis of PSC liver samples were conducted. In vitro studies on a human cholangiocyte cell line (NHC), U937 and human hepatic stellate cells (hSteCs) were performed. Additionally, Abcb4 −/− mice were treated with BAR501 for 12–24 weeks.

Results

Single‐cell analysis demonstrated that GPBAR1 is expressed by macrophages, NK cells, sinusoidal cells and to a lesser extent by cholangiocytes. Total liver expression of GPBAR1 increases in PSC patients compared to that in healthy controls and positively correlates with markers for monocytes and NK cells and cytokeratin 19. In vitro treatment of NHCs with BAR501 reversed the acquisition of a pro‐inflammatory phenotype and the downregulation of GPBAR1 expression promoted by LPS in an NF‐κB‐dependent manner. Treating Abcb4 −/− mice reduced bile duct inflammation and liver fibrosis and prevented the downregulation of GPBAR1 expression. Treating mice with BAR501 also modulated the bile acid pool composition and reduced the dysbiosis‐associated gut permeability, and intestinal and systemic inflammation. Ex vivo experiments using conditioned media from BAR501‐treated cholangiocytes mitigated the activation of macrophages.

Conclusions

Our study provides evidence for the therapeutic potential of selective GPBAR1 agonists in intestinal inflammation–associated cholestasis, warranting the evaluation of BAR501 in PSC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingReceptors, G-Protein-CoupledCholestasisLiverAnimalsHumansMiceATP Binding Cassette Transporter, Subfamily BMice, KnockoutDisease Models, AnimalMaleFemaleHepatic Stellate Cells

Stichwörter der Autor:innen

GPBAR1 (TGR5)bile acidscholangiocytes–macrophages cross‐talkgut–liver axesintestinal microbiotaprimary sclerosing cholangitis

Substanzen

Receptors, G-Protein-CoupledGPBAR1 protein, humanATP Binding Cassette Transporter, Subfamily BGpbar1 protein, mouse

Autor:innen und Institutionen

  • Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
  • BAR PHARMACEUTICALS SRL, Reggio Emilia, Italy.
  • Department of Pharmacy, University of Naples Federico II, Naples, Italy.
  • Azienda Ospedaliera di Perugia, Perugia, Italy.
  • Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), CIBERehd, Donostia-San Sebastian, Spain.
  • IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.

ORCID-Profile: Cristina Di Giorgio, Michele Biagioli, Luigi Cari, Elva Morretta, Maria Chiara Monti, Piotr Milkiewicz

Förderung

  • PRIN-2022 n. 20223K7L88
  • FIS PI24/00148, PI21/00922
  • PRIN-2022-PNRR n. 20227JB3W
  • Miguel Servet CPII19/00008

Zitieren

APA

Di Giorgio, C., Urbani, G., Marchianò, S., Biagioli, M., Bordoni, M., Bellini, R., Massa, C., Lachi, G., Cari, L., Morretta, E., Spinelli, L., Monti, M. C., Sepe, V., Zampella, A., Distrutti, E., Banales, J. M., Lapitz, A., Milkiewicz, P., Milkiewicz, M., & Fiorucci, S. (2025). Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice. Liver International, 45(2). https://doi.org/10.1111/liv.16235

Vancouver

Di Giorgio C, Urbani G, Marchianò S, Biagioli M, Bordoni M, Bellini R, et al. Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice. Liver International. 2025;45(2). doi:10.1111/liv.16235

BibTeX
@article{DiGiorgio2025,
  author = {Di Giorgio, Cristina and Urbani, Ginevra and Marchianò, Silvia and Biagioli, Michele and Bordoni, Martina and Bellini, Rachele and Massa, Carmen and Lachi, Ginevra and Cari, Luigi and Morretta, Elva and Spinelli, Lucio and Monti, Maria Chiara and Sepe, Valentina and Zampella, Angela and Distrutti, Eleonora and Banales, Jesus M and Lapitz, Ainhoa and Milkiewicz, Piotr and Milkiewicz, Malgorzata and Fiorucci, Stefano},
  title = {Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {2},
  doi = {10.1111/liv.16235}
}
Kostenlos starten →